Efficacy and safety of teclistamab followed by autologous stem cells transplant in functional high-risk and triple class refractory multiple myeloma. Mediterranean Journal of Hematology and Infectious Diseases, [S. l.], v. 17, n. 1, p. e2025051, 2025. DOI: 10.4084/MJHID.2025.051. Disponível em: https://www.mjhid.org/mjhid/article/view/5994. Acesso em: 1 may. 2026.